Changes in Metabolomic Profiles Induced by Switching from an Erythropoiesis-Stimulating Agent to a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor in Hemodialysis Patients: A Pilot Study

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are a new class of medications for managing renal anemia in patients with chronic kidney disease (CKD). In addition to their erythropoietic activity, HIF-PHIs exhibit multifaceted effects on iron and glucose metabolism, mitochondrial...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Kimio, Sato, Emiko, Mishima, Eikan, Moriya, Shinobu, Sakabe, Takuma, Sato, Atsuya, Fujiwara, Momoko, Fujimaru, Takuya, Ito, Yugo, Taki, Fumika, Nagahama, Masahiko, Tanaka, Kenichi, Kazama, Junichiro James, Nakayama, Masaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454178/
https://www.ncbi.nlm.nih.gov/pubmed/37628932
http://dx.doi.org/10.3390/ijms241612752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454178/
https://www.ncbi.nlm.nih.gov/pubmed/37628932
http://dx.doi.org/10.3390/ijms241612752

Ejemplares similares